We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Crystallics - a New Company with a Long History in Pharmaceutical Development
News

Crystallics - a New Company with a Long History in Pharmaceutical Development

Crystallics - a New Company with a Long History in Pharmaceutical Development
News

Crystallics - a New Company with a Long History in Pharmaceutical Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Crystallics - a New Company with a Long History in Pharmaceutical Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Avantium Pharma BV, has been spun out from Avantium Holding BV in a management buy-out to create Crystallics.

The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for pharmaceutical and biotechnology companies, as well as, pharmaceutical contract manufacturing organizations and agrochemical companies.

Gunnar Staaf, Chief Executive Officer, commented: “Crystallics’ core business focus will be in solid state research and pre-formulation, an area where we have built up considerable expertise over the last decade. I believe our proprietary technology, experienced team, together with a strong customer focus, make Crystallics an ideal partner.”

Solid state research plays a central role in the pharmaceutical industry. Active pharmaceutical ingredients can exist in a number of solid forms, such as polymorphs, salts, co-crystals, hydrates, or amorphous forms.

Various solid state forms of the same active pharmaceutical ingredient will have different characteristics that can have a significant impact on the safety and efficacy of a drug product.

Marcel Hoffmann, Chief Scientific Officer, said: “We believe in a tailored, science based approach to meet the customer’s project objectives and budgets. Quality and speed will be at the heart of our research approach.”

Advertisement